Welcome to Nofinity

In this episode of The Drive, Peter Attia explores the controversial world of peptides. He provides a framework to critically evaluate them, distinguishing legitimate science from marketing hype.

What Are Peptides?

• Short chains of amino acids – the term alone says nothing about safety or efficacy.
• Often marketed as "natural," but most are synthetically modified (e.g., longer-acting, tighter binding).

Evaluation Framework (5 Questions):

1. Plausible mechanism of action? – Defined molecular target and downstream effects?
2. Evidence of meaningful benefit in humans? – Randomized controlled trials (RCTs) available?
3. Known safety, dosing, pharmacokinetics? – How does it enter circulation, how long does it last, what are the risks?
4. Does the likely benefit justify the risk for this individual? – Is the risk acceptable given the expected benefit?
5. Are there better-characterized alternatives? – Why not use an approved, well-studied drug instead?

Three Categories of Peptides:

• Category 1: Scientifically unsupported – No validated mechanism, no human evidence.
  • Example: BPC‑157 – No known receptor, no published RCTs, >80% of studies from one group with financial interests. Claims have expanded for 30 years without answering basic questions.
• Category 2: Biologically plausible, but no clinical evidence – Mechanism conceivable, but no demonstrated improvement in patient-relevant outcomes.
  • Example: CJC‑1295 – Increases GH/IGF‑1, but functional benefits (strength, recovery) in healthy individuals are unproven. The drug was abandoned by its developer.
• Category 3: Scientifically legitimate molecules – Efficacy proven for specific indications.
  • Example: GLP‑1 agonists (e.g., semaglutide) – Effective for obesity/diabetes, but evidence applies only to the specific tested product, not gray-market copies.

Anecdotes vs. Evidence

• Subjective success stories are often confounded by placebo effect, regression to the mean, or concurrent interventions (exercise, diet, other drugs).
• Randomized controlled trials isolate the molecule's effect from expectation.

FDA and the Gray Market

• FDA approval provides information on efficacy, safety, dosing, manufacturing quality, and post-market surveillance.
• Gray-market peptides bypass these standards: unknown pharmacokinetics, uncertain purity, lack of batch consistency.
• Even with identical sequence, a gray-market product is not equivalent – manufacturing processes alter drug properties.
• Many gray-market peptides were abandoned during pharmaceutical development (e.g., CJC‑1295, because tesamorelin had better data).

Conclusion

• Peptides are a legitimate and powerful drug class (insulin, GLP‑1).
• The hype around gray-market peptides is often unjustified: claims are not falsifiable, evidence does not precede use.
• For healthy individuals, the bar should be high: only use if there is a clear indication, proven benefit, and controlled quality.
• Evidence should come before use – not the other way around.

Summary follows...

The 2 Amino Acids That Restore Muscle Strength & Burn 78% More Fat

This summary analyzes a study on GlyNAC (Glycine + N-Acetylcysteine) and its effects on mitochondrial health, muscle strength, and fat metabolism in older adults.

• Mitochondrial Dysfunction: Aging muscle cells lose the ability to efficiently burn fatty acids.
• Glutathione Deficiency: Intracellular glutathione, the cell's master antioxidant, is reduced by up to 70% in older adults.
• Root Cause: Two rate-limiting building blocks – glycine and cysteine – are equally depleted with age.

• Mechanism: The cell needs both amino acids to produce glutathione. Glycine and NAC provide the missing components.
• Study Design: 24 overweight older adults (61-80 years) received 100 mg/kg glycine + 100 mg/kg NAC daily (approximately 9 g per amino acid for a 90 kg person) for 16 weeks.

• Glutathione Increase: +225% in red blood cells, +164% in muscle biopsies – reaching levels of young adults.
• Fat Oxidation: +78% increase.
• Muscle Strength:
  • Gait Speed: +0.21 m/s (matching young adult levels)
  • Grip Strength: +4.4 kg (dominant hand)
  • Chair Rise Test: -6.8 seconds (better leg power)
• No Muscle Gain: Lean mass remained unchanged. Strength gains resulted from improved mitochondrial efficiency.

• Anti-Inflammatory: Interleukin-6 decreased by 78%, TNF-alpha by 54%, protective interleukin-10 nearly doubled.
• Insulin Resistance: HOMA-IR decreased by 64%.
• Oxidative Stress: DNA damage markers dropped by 73%.
• Blood Pressure: Systolic decreased from 132 to 124 mmHg.

• High Dosage: The study used very high doses (18 g of amino acids daily). Lower doses have not been tested.
• No Sustained Effect: After stopping GlyNAC, glutathione levels and strength gains returned to baseline.
• Lifespan Extension: The often-cited 24% lifespan increase comes from a mouse study, not human data.

GlyNAC addresses a core cause of age-related strength and energy loss: glutathione deficiency. The results are promising but require medical supervision, especially at high doses and regarding potential drug interactions.

• A 49-year-old sets the ambitious goal to dunk a basketball – a symbol of youthful athleticism and vitality.
• He trains with a professional coach who works with NBA players and has been at it for nearly 3 months.

• Instead of abstract metrics like VO2max (which he previously pushed to elite 18-year-old levels), he now focuses on a visible, relatable target.
• A dunk resonates with people: „The best biomarker I could ever achieve.“

• Phase 1 (first 2 months): Build a strong physiological base – especially tendon health and stiffness (tendons adapt in 8–12 weeks, muscles in 3–4).
• Phase 2 (from month 3): Add strength (for force production) and later speed (rate of force development).
• Current vertical jump measurement: 23.9 inches (approx. 60.7 cm) – baseline.

• After 3 months he feels clear gains and more trust in his body.
• The coach estimates an 80–85% success probability – aided by lean physique, good nutrition and sleep.
• Key: precise execution of drills (e.g., knees over toes in squats, bouncy movements).

„It‘s not about stopping the negative, it‘s about doing the positive.“ – The journey to a dunk is a statement against age limits.

• Clarity Act Fails: The first major US crypto regulation bill died in the Senate (49:50, 10 votes short). Coinbase stock fell 8%, Circle ~10%. Bitcoin ignored it.
• Fed Rate Hike: The US Federal Reserve raised rates by 25 basis points (first since 2023). The 10-year Treasury yield spiked above 5%, the Bank of Japan hiked to a 31-year high. Bitcoin still rose.
• AI Sector Weakens: Anthropic's CEO warned about runaway AI progress. Sam Altman and Elon Musk agreed. The semiconductor index dropped over 5%; Nvidia, ASML, SoftBank all fell. Crypto remained unfazed.

• 84% of liquidations were shorts ($843M of $1B total).
• In a single hour, over $300M was liquidated, 97% of it shorts.
• Between 126,000 and 135,000 accounts were closed.
• One wallet lost 375 BTC (~$32.5M) in four sequential liquidations over 14 hours.
• Mechanics: Forced buying from short liquidations pushes price higher → triggers next layer of shorts → cascade.

• Clarity Act irrelevant for markets: A failed bill changes nothing about Bitcoin's functionality (blocks, trades, custody). Crypto grew to over $1 trillion without US regulation.
• Institutions keep buying:
  • Strategy (MicroStrategy) bought 950 BTC for $75M right in the worst news week.
  • US spot Bitcoin ETFs lost $450M on voting day, but regained $433M just three sessions later.
  • Morgan Stanley's Bitcoin ETF logged 20 consecutive days of net inflows.

• China ban 2021: >50% of global hashrate went offline → Bitcoin rose from $29K to new ATH in 4 months.
• FTX collapse Nov 2022: Low of $15,400 – the absolute bottom.
• US banking crisis March 2023: Three banks failed, USDC depegged → Bitcoin rallied 40%.
• Inverse: Coinbase IPO April 2021 (peak) and ETF approval January 2024 (price fell from 49K to 38K) – good news marked tops.

Bitcoin is not a market that only rises on good news. The current rally through three parallel shocks shows: A strong holder base and institutional demand drive price independently of politics and macro. Future headlines may be just as grim – but crypto has proven itself through years of uncertainty and hostility. The question: Higher from here, or a bull trap?

Kaspi.kz (NASDAQ: KSPI) is a super app from Kazakhstan that covers nearly the entire financial and daily life of the country. The stock offers a dividend yield of almost 9 %, a P/E ratio of about 7, and growth of around 17 % – for the analyst, it's hard to find much wrong.

• Monopoly position: 85 % of payment processing and 70 % market share in consumer commerce in Kazakhstan.
• Government integration: Deep cooperation with the government and central bank – considered “too big to fail.” After a short-seller report (Culper Research), regulators immediately defended the company.
• Super app: Used for healthcare, government services, and banking – practically the entire population depends on it.
• Monopoly with political backing: This only works in Kazakhstan, but there it is a legal money-printing machine.

• Acquisition of Turkish e-commerce leader Hepsiburada for $1.1 billion.
• Acquisition of a banking license (Rabobank license) and planned capital injection of $300 million.
• Expansion of a “Buy Now, Pay Later” business and integration of fintech solutions into the Turkish platform.
• If Turkish profitability even approaches Kazakh levels, this could become a major winner.

• Net income is growing, stable net margin of around 27 %.
• E-commerce growth and payment business are strong thanks to the monopoly position.
• Non-performing loans (NPL): About 6–7 % and slightly rising – worth watching, but cushioned by high interest rates (15 % central bank rate).
• Balance sheet: $15 billion in customer loans, $17 billion in customer deposits – typical bank risks, but with fintech margins.

• Kazakhstan risk: Political connections, corruption allegations, possible rumors about bank stability.
• Dependence on the state: If political support changes, the business model would be in danger.
• Currency risk: Tenge fluctuations, but growth remains strong when measured in dollars.
• Bank risk: As a financial company, always vulnerable to loss of confidence and potential bank runs.

• P/E of 8 with 15 % growth and an 8–9 % dividend yield provide a margin of safety.
• Tencent as an investor and the “Silk Belt and Road” connection to China are additional strategic pluses.
• Founders own 66 % of the capital – without them the construct would not work, which creates resilience.
• The analyst is considering adding the stock to his diversified portfolio, although he considers the environment risky. “Hard to find much wrong” – but it remains an engaged emerging-market investment.

The Bitcoin price has surged from $68,000 to $87,000 in just two weeks, approaching the predicted October target of $90,000. Exchange-traded funds (ETFs) are seeing strong inflows, and long-term holders have significantly reduced their selling, which is considered a bullish signal. The price has broken through the 50-week moving average, suggesting further gains, while institutional investors are increasingly using MicroStrategy to gain exposure to Bitcoin. The purchasing power of the US dollar continues to decline due to inflation.